New study examines characteristics of women with an aggressive form of breast cancer

July 05, 2005

Women with a relatively rare and aggressive form of breast cancer tend to be younger, have larger tumors, and have a poorer survival rate compared with women with the most common forms of the disease, reports a new study in the July 6 issue of the Journal of the National Cancer Institute.

Inflammatory breast carcinoma (IBC) is a relatively rare and understudied type of breast cancer characterized by redness, warmth, and swelling, often without an underlying palpable mass. However, case definitions for the disease vary, so estimates for how often it occurs have ranged widely from less than 1% to 10% of breast cancer cases.

To learn more about the incidence and characteristics of IBC, Kenneth W. Hance, Ph.D., M.P.H., of the National Cancer Institute (NCI) in Bethesda, Md., and colleagues studied data from the Surveillance, Epidemiology, and End Results (SEER) program on more than 180,000 breast cancer cases diagnosed between 1988-2000. SEER is a large database managed by the NCI that collects data from cancer registries across the country that cover about 26% of the U.S. population.

The authors calculated that IBC comprised about 2% of all breast cancer cases and that women were diagnosed with IBC at an average age of 58.8 years--about 3 to 7 years younger than the average age of women diagnosed with other forms of breast cancer. In addition, patients with IBC had a poorer survival rate, with a median survival of 2.9 years after diagnosis compared with 6.4 to 10 years for other types of breast cancer. Black patients with IBC had a poorer survival rate than white patients. On average, IBC tumors tended to be larger than those in other forms of breast cancer.

They found that the number of cases of IBC appears to be rising; the incidence rate increased between 1988 and 1999 from 2.0 cases per 100,000 women to 2.5 per 100,000. (By comparison, the incidence of more common forms of breast cancer decreased from 108 cases per 100,000 women to 101 per 100,000 during the same time period.) Black women had a higher incidence rate of IBC--3.1 cases per 100,000 women--compared with white women (2.2 cases per 100,000 women). The authors cite heightened clinical awareness and changing patterns of risk factor exposure as possible explanations for the rise in reported cases.

Although they report that their study helps create a comprehensive definition for IBC in the SEER database, the authors state that finding a molecular determinant and genetic profile for the disease is still needed to "facilitate our understanding of the etiology of this disease, and ... to identify IBC subtypes that may possess common therapeutic responses and clinical outcomes," they write.
-end-
Contact: Barbara Porter, GW Medical Center, 202-994-3121, mcmbap@gwumc.edu
NCI Press Office, 301-496-6641, ncipressofficers@mail.nih.gov

Citation: Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-75

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.